EBV-Mir-BART5-5p targets p53 independent pathway in cytoplasm: Potential role in EBV lymphomagenesis

Wei‐Ting Wang(Institute of Molecular Biology, Academia Sinica), Wei Xu(Second Military Medical University), Hao-Rui Shen(Nanjing Medical University), Yi Xia(Nanchang University), Jianyong Li(Jiangsu Province Hospital), Jia‐Zhu Wu(Augusta University Health), Jin‐Hua Liang(Broad Institute), Li Wang(University of Science and Technology of China), Jing-Ran Guo(Jiangsu Province Hospital)
Genes & Diseases
August 19, 2022
10.1016/j.gendis.2022.07.003
Cited by 7

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U
|The Journal of Experimental Medicine|2010|240
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|238